2024-10-04
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
financial news agency, october 4 (editor xuan lin)according to reports, wu yihuan, vice chairman of the shenzhen municipal people’s political consultative conference, led a team to shenzhen sunshine medical beauty hospital on september 29 to carry out “strengthening the protection of consumer rights and interests” in 2024.special democratic supervision of medical beauty consumption. shenzhen municipal health commission will guide the quality control centerformulate shenzhen medical beauty quality control standards, organize quality evaluation of medical beauty institutions,improve the quality and level of medical beauty services in the city。
in the secondary market,aimike, the leading medical beauty company, recorded two consecutive gains of 20cm at the closing price on september 30.。
shanghai securities liang rui said in a research report on september 29 that the central bank recently announced a reduction in existing mortgage interest rates and unified the minimum down payment ratio for mortgages. shanghai recently decided to issue "le·shanghai" to four areas including catering, accommodation, movies, and sports. service consumption coupons,this time, the policy of lowering existing mortgage interest rates and promoting consumption policies is expected to boost pessimistic sentiment about consumption. it is recommended to pay attention to the valuation restoration of the beauty care sector.。
liang duanyu of bank of china securities said in a research report on july 4 that haohai biotech’s annual report showed that from 2017 to 2021, the size of china’s medical beauty market increased from 99.3 billion yuan to 189.2 billion yuan.the average annual compound growth rate is 17.5%. according to allergan and deloitte's "china's medical aesthetics industry 2023 insight report", the impact of the epidemic on the medical aesthetics industry in 2022 will be the same as the market size in 2021.in 2023, with the help of post-epidemic consumption recovery, year-on-year growth can reach 20%, and maintain a rapid growth of 15% from 2023 to 2027,it is expected that china’s medical beauty market will reach 397.1 billion yuan in 2027。
liang duanyu said that there is growth potential in all subdivisions of the medical beauty industry, among whichhyaluronic acid injection productsit is relatively mature and is often used as a diversion project by downstream institutions.it is expected to achieve rapid growth with the acquisition of customers by medical beauty institutions.;regenerative medical beauty marketdevelopment in china is in the ascendant;collagen injection marketthere is also blue ocean space.
data shows that hyaluronic acid filling was mainly used for wrinkle removal, facial filling and contour filling in the early days. now it can also be used to fill between facial bones and ligaments to prevent facial sagging. according to soyoung data, only 23% of hyaluronic acid project functional requirements in 2021 are anti-aging.the proportion of this demand has reached 40% in 2022。the potential market demand in the anti-aging field is far greater than the demand for appearance change, with the increasing recognition of hyaluronic acid in the field of anti-aging,market space is expected to further increase. at the same time, the purpose of anti-aging is difficult to achieve through daily skin care, so it is difficult to "downgrade". according to iresearch data, 52.2% of medical aesthetics consumers have received water-light injections in 2022.43.6% of consumers have received hyaluronic acid filler injections, 33.70% of consumers have received hiti family injections.
there are many categories of hyaluronic acid. currently, more than 15 manufacturers have approved hyaluronic acid injection products, includingamic, bloomage biotech, haohai biotech, lg life, allergan, galderma, humedixetc., with more than 30 product categories.
in terms of regenerative medical beauty, after injecting regenerative medical beauty products, the microspheres cause damage at the junction of the epidermis and dermis of the skin, stimulating the production of collagen in specific areas, thereby increasing skin volume, restoring skin structure and reshaping firm skin.compared with hyaluronic acid filling, regenerative medical aesthetics lasts longer and the effect is more natural., and due to the high requirements for doctors and the high production process threshold, oftentargeting the high-end market. regenerative medical beauty injection products currently on the market in china include girl injections, child facial injections, etc.the prices are all higher than 10,000 yuan。
currently, there are few approved products in the regenerative medical beauty market. according to frost & sullivan data, only four products are currently approved in china: changchun st. boma's löviselle (aiweilan) child beauty injection, huadong medicine's ellansé (eyanshi) girl injection, aimeike's moisturizing angel and jiangsu wuzhong's aesthefill。
in terms of collagen injection, currently, there are only a small number of domestically approved collagen injection products, and most of them are animal-derived collagen. liang duanyu said,recombinant collagen has better biocompatibility and efficacy than animal collagen, although the production cost is high, recombinant collagen has no viral risks and low immunogenicity.has greater room for market expansion. currently, the only two compliant recombinant collagen medical beauty products approved in china arejinbo bio’s “recombinant type iii humanized collagen lyophilized fiber” wei yimei and “recombinant type iii humanized collagen solution for injection”, among which the sales volume of weiyimei in 2023already more than 570,000 bottles。